Printer Friendly

Anatomic Distribution of Sessile Serrated Adenoma/Polyp With and Without Cytologic Dysplasia.

Colorectal cancer (CRC) is the third most common cancer diagnosed in men and women and is the third leading cause of cancer death in the United States. (1-3) About 80% to 85% of CRCs are thought to arise from preexisting adenomas resulting from the Adenoma Polyposis Coli (APC) gene mutation through the chromosome instability pathway. (4,5) The remaining 15% to 20% of CRCs are believed to develop through the microsatellite instability pathway, as exemplified by the 3% to 5% of CRC patients with Lynch Syndrome and the 10% to 12% of CRC patients with epigenetic alteration or epigenetic instability due to CpG island methylator phenotype and hypermethylation, both manifested as microsatellite instability pathway cancers. (5-8) Screening colonoscopy with polyp removal is an effective method to reduce the incidence of and mortality from CRC. (9,10) In the United States, although the age-adjusted incidence of distal colon cancer has steadily decreased from 1976 to 2005, the incidence of right-sided colon cancers remains unchanged, (11) likely at least in part because of underdetected and/or underdiagnosed sessile serrated adenomas/polyp (SSA/P).

At this institution, Lash et al (12) previously reported on a different cohort of patients with SSA/Ps and found that they were more prevalent in women in the right colon (including transverse colon), and that SSA/Ps with cytologic dysplasia and carcinoma occurred disproportionately among older women and over a long period of time, based on median age. The current study is designed to further characterize the specific anatomic distribution of SSA/P with and without cytologic dysplasia. Also, recently updated criteria (8) have resulted in classifying what was previously considered "borderline or indeterminate" serrated polyp as true SSA/ P, and the authors also wanted to determine whether this more inclusive group of SSA/P shares the same distribution and demography.


Study Design and Database

This retrospective study was conducted at Miraca Life Sciences Research Institute (Irving, Texas) and was approved by the Miraca Institutional Review Board. Miraca Life Sciences is a national specialized anatomic pathology laboratory that includes a large subspecialty gastrointestinal pathology practice. It receives specimens primarily from community-based ambulatory endoscopy and surgery centers throughout the United States.

The Miraca Life Sciences database was queried for SSA/P with and without cytologic dysplasia and adenocarcinoma from January 1, 2009, to December 31, 2009, including patients' demographics, clinical information, endoscopic findings, specimen sites, and corresponding pathologic findings. Specimen sites of SSA/P with cytologic dysplasia and/or carcinoma were then confirmed manually.

The pathologic criteria for the diagnosis of SSA/Ps were based on Torlakovic and Snover, (13) Torlakovic et al, (14) and Snover et al (15) regarding morphologic reappraisal of serrated colorectal polyps. Cytologic dysplasia was assessed based on previously described criteria (16-18) and was routinely confirmed at the daily departmental consensus conference (examples are demonstrated in Figure 1). The diagnosis of SSA/P with dysplasia or carcinoma required the presence of dysplasia/carcinoma in the same tissue fragment(s) as the SSA/P.

Our SSA/P group included 4541 patients (42.7%) with polyps that were originally classified as "borderline or indeterminate" serrated polyps, a classification based on more conservative criteria existing at that time, (19) typically because of a limited number of basally dilated glands in an otherwise sessile serrated configuration. A recent expert consensus recommendation has defined SSA/ P more liberally, requiring only "a single crypt with unequivocal dilatation, distortion, and/or horizontally branched crypt." Based on these newly published criteria, the formerly designated "borderline or indeterminate" serrated polyp would be classified as SSA/P. (8) Traditional serrated adenomas, hyperplastic polyps, and tubular adenomas were not included in this study.

The patients were then subgrouped and analyzed by age, sex, degree of cytologic dysplasia, and anatomic site.

Study Definition of Anatomic Sites of the Colon

In this study, anatomic sites were based on their original specimen requisitions submitted by endoscopists, except when specimens (164 patients; 1.46%) were labeled by the distance from the anal verge. For these, the anatomic site was "translated" into a specific site based on the following: <15 cm (rectum), 15 to 17 cm (recto-sigmoid), 17 to 57 cm (sigmoid), 57 to 82 cm (descending), 82 to 132 cm (transverse), 132 to 147 cm (ascending), and 150 cm (cecum). Those requisitions that failed to provide clearly written specimen site information, those specimens that were labeled as "random," and those specimens without any specific designation

Statistical Analysis

All quantitative data were summarized by mean and standard deviation (mean [+ or -] SD), and count data were given their corresponding percentage (%). The collected quantitative and count data were then subgrouped and analyzed using Student t test or [chi square] test. A P value less than or equal to .05 was considered to be significant. All statistical analyses were performed using SigmaStat 3.5 software (San Jose, California).


Patients' Demography

A total of 11 201 patients (6.3%) with 13 072 SSA/P specimens were identified among 178 963 patients (49.6% women; mean age 59.3 [+ or -] 13.3 years, ranging from 3 months to 106 years) who received colonoscopy, with a total of 180 948 colonoscopy specimens dating from this period of time in our database. Among them, 10 646 patients (95.0%) had SSA/P, 514 patients (4.6%) had SSA/P with low-grade cytologic dysplasia (SSA/P-LGD), 39 patients (0.35%) had SSA/P with high-grade cytologic dysplasia (SSA/P-HGD), and 2 patients (0.018%) had SSA/P with adenocarcinoma (SSA/P-ACA).

There were more women than men in all studied groups: 4965 men (46.6%) versus 5681 women (53.4%) had SSA/P; 209 men (40.7%) versus 305 women (59.3%) had SSA/P-LGD; 11 men (28.2%) versus 28 women (71.8%) had SSA/ P-HGD, and the 2 patients with SSA/P-ACA were both women (100%). The mean age differences of SSA/P with and without cytologic dysplasia were significant in SSA/P (60.8 [+ or -] 11.2 years), SSA/P-LGD (65.6 [+ or -] 11.1 years), and SSA/P-HGD (69.9 [+ or -] 9.3 years; Table 1). The mean age differences of patients with SSA/P versus LGD and LGD versus HGD were 4.8 and 4.3 years, respectively (total, 9.1 years). Further, the percentage of women among each advancing lesion was significantly and increasingly higher than men.

Distribution in the Colon

Sessile serrated adenoma/polyps with and without cytologic dysplasia or carcinoma occurred throughout the entire colon but were concentrated in certain areas (graphically demonstrated in Figure 2; Table 2). Sessile serrated adenoma/polyp was significantly more prevalent in the proximal colon than the transverse and distal colon (Figure 3): 61.2% versus 18.8% in the transverse colon (P <.001) and 19.9% in the distal colon (P <.001). There was no statistical difference in the prevalence of SSA/P in the transverse versus distal colon (P =.08).

The distribution of SSA/P-LGD in the colon was similar to SSA/P: 61.2% SSA/P-LGD in the proximal colon versus 17.8% in the transverse colon (P <.001) and 21.0% in the distal colon (P <.001). There was no significant difference between the prevalence of SSA/P-LGD in the transverse and distal colon (P =.31). Among them, there were 18 patients (18 of 514; 3.5%; men, n = 6; women, n = 12; average age, 65.7 years) with [greater than or equal to] 2 SSA/P-LGDs (one patient had 4 SSA/P-LGDs and the remaining had 2 SSA/P-LGDs), which showed as having a similar distribution: cecum (4; 10.5%), ascending (10; 26.3%), hepatic-flexure (6; 15.8%), transverse (10; 26.3%), splenic-flexure (1; 2.6%), descending (2; 5.3%), sigmoid (4; 10.5%), rectosigmoid (0; 0%), and rectum (1; 2.6%).

Sessile serrated adenoma/polyp-HGD and SSA/P-ACA also had distribution patterns similar to their less advanced counterparts: 80% of SSA/P-HGDs and 2 SSA/P-ACAs were both in the cecum/ascending colon (P <.001), whereas 10.0% of SSA/P-HGDs were evenly distributed in the transverse and the distal colon (Figure 3). As with SSA/ P, the prevalence of SSA/P with cytologic dysplasia and carcinoma showed a similarly low prevalence in the transverse and distal colon relative to the proximal colon (P <.001).

The most likely specific site to harbor an SSA/P-HGD was the cecum (15 of 40; 37.5%), and the highest prevalence of SSA/P-LGD was in the ascending colon (169 of 534; 31.6%), shown in Table 2. One SSA/P-ACA was found in the cecum, and the other was located in the ascending colon.


It is now understood that serrated polyps have molecular and clinical attributes that differ from nonserrated adenomas. (6-8,20) The serrated polyp family members include the microvesicular hyperplastic polyp, goblet cell-rich hyperplastic polyp, traditional serrated adenoma, filiform serrated adenoma, and SSA/P. The prevalence of SSA/P ranges from 0.6% to 9% of all colonic polyps, (12,21-24) and reported risk factors for SSA/P include older age, female sex, smoking, diabetes mellitus, and obesity. (12,25,26)

The importance of the "serrated" pathway with SSA/P and more advanced lesions is now recognized. Patients with SSA/Ps are more likely to have a greater polyp burden, have other synchronous and metachronous neoplasms, and are believed to represent the precursor to about 15% to 30% of sporadic CRCs. (6,20) Therefore, it is recommended from a recent expert consensus review that all proximal serrated polyps, proximal polyps >10 mm diagnosed as hyperplastic polyp, serrated lesions proximal to the sigmoid colon, and serrated lesions in the rectosigmoid colon >5 mm be completely removed when possible. (8,27,28)

This study specifically maps the anatomic location of SSA/ P with and without cytologic dysplasia or carcinoma (beyond the broad categories "right" and "left" colon), including previously considered "borderline or indeterminate" serrated polyp. We found that right-sided SSA/P and more advanced lesions were concentrated in the cecum and ascending colon, with the distribution in the transverse colon matching the low rate in the distal colon. As mentioned, this study included a large group of previously designated "borderline or indeterminate" serrated polyps that, according to updated criteria, should be considered true SSA/Ps. This cohort, using newer, more inclusive criteria for SSA/P, featured the same demographic and anatomic distribution described previously. (12) This study also confirmed, on a 5-fold larger cohort, the key elements of the previous findings from this institution regarding a separate group of SSA/Ps, (12) specifically an approximately 5-year difference between the mean ages for each progressive stage from SSA/P to SSA/P-HGD, as well as the female and right-sided predominance. Such confirmation of a different cohort of patients not only confirms the prior data but also indicates that the newer criteria for SSA/P (inclusive of the formerly designated "borderline or indeterminate" serrated polyp) appear to be valid. (8)

In this study, our data also show that 18 patients (3.5%) had multiple synchronous SSA/P-LGD. This subgroup with multiple lesions showed a similar female predominance (67%) and mean age (65.7 years) as that of the general SSA/ P-LGD group. Although this group of patients might meet the criteria of serrated polyposis syndrome, (6,29-31) we do not have sufficient clinical data to determine the prevalence of serrated polyposis syndrome in our cohort.

After excluding patients who had previously been designated as having "borderline or indeterminate" serrated polyp, the prevalence of SSA/P with LGD, HGD, and CRC in our cohort (7.7%, 0.59%, and 0.03%, respectively) was still lower than the reported rates in the prior study from this institution (12%, 2%, and 1%). (12) We believe that the differences of prevalence of SSA/P with cytologic dysplasia and carcinoma between the 2007 study and this study are due to not only more inclusive pathologic criteria but also increased recognition of more subtle (and therefore likely nondysplastic) SSA/Ps by endoscopists. The endoscopic appearance of SSA/P is shown in Figure 4.

It is worth mentioning that the low rate of diagnosis of invasive CRC arising in the background of SSA/P in this study is most likely due to the fact that biopsy specimens are limited in quantity and often do not demonstrate both carcinoma and the preexisting SSA/P.

In conclusion, SSA/P with and without cytologic dysplasia or carcinoma occurs most commonly in the cecum and ascending colon, and occurs similarly less frequently in the transverse and distal colon. Highly advanced SSA/Ps (SSA/ P-HGD and SSA/P-ACA) are also most commonly found in the cecum and ascending colon. The inclusion of recently published, more inclusive criteria of patients with SSA/P does not appear to alter the age and sex relationships previously reported. Further, based on mean ages, neoplastic progression from SSA/P to SSA/P-LGD and then to SSA/ P-HGD appears to take about 5 years for each step. Advanced lesions occur increasingly and disproportionately among older women. The increased number of patients with the diagnosis of SSA/P is likely due to increased awareness by both endoscopists and pathologists. Endoscopic screening and detection of SSA/P and more advanced lesions need to be focused on high-risk groups (older women) and high-risk locations (cecum and ascending colon).

Please Note: Illustration(s) are not available due to copyright restrictions.

The authors wish to acknowledge the significant contributions of Robert Genta, MD, for reviewing the manuscript and providing important assistance with the database, and Suzanne Ridner, BS, for providing valuable administrative support.


(1.) Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008; 134(5):1570-1595.

(2.) Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30.

(3.) Qaseem A, Denberg TD, Hopkins RH Jr, et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med. 2012; 156(5):378-386.

(4.) Grady WM, Carethers J. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008; 135(4):1079-1099.

(5.) Centelles JJ. General aspects of colorectal cancer. ISRN Oncol. 2012; 2012: 139268.

(6.) Snover DC, Ahnen DJ, Burt RW, et al. Serrated polyps of the colon and rectum and serrated polyposis. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC Press; 2010:160-165.

(7.) O'Brien MJ, Yang S, Mack C, et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol. 2006; 30(12):1491-1501.

(8.) Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012; 107(9):1315-1329.

(9.) Brenner H, Haug U, Arndt V, Stegmaier C, Altenhofen L, Hoffmeister M. Low risk of colorectal cancer and advanced adenomas more than 10 years after negative colonoscopy. Gastroenterology. 2010; 138(3):870-876.

(10.) Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012; 366(8): 687-696.

(11.) Cheng L, Eng C, Nieman LZ, Kapadia AS, Du XL. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol. 2011; 34(6):573-580.

(12.) Lash RH, Genta RM, Schuler CM. Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. J Clin Pathol. 2010; 63(8):681-686.

(13.) Torlakovic C, Snover DC. Serrated adenomatous polyposis in humans. Gastroenterology. 1996; 110(3):748-755.

(14.) Torlakovic C, Skovlund E, Snover DC, et al. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol. 2003; 27(1):65-81.

(15.) Snover DC, Jass JR, Fenoglio-Preiser C, et al. Serrted polyps of the large intestine: a morphologic and molecular review of an envolving concept. Am J Clin Pathol. 2007; 124(3):380-391.

(16.) Abraham SC, Burgart LJ, Odze RD. Polyps of the large intestine. In: Odze RD, Goldblum JR, Crawford JM, eds. Surgical Pathology of the GI Tract, Liver and Pancreas. 1st ed. Philadelphia, PA: Saunders; 2004:347.

(17.) Goldstein NS. Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases. Am J Clin Pathol. 2006; 125(1):132-145.

(18.) Sheridan TB, Fenton H, Lewin MR, et al. Sessile serrated adenocarcinomas with low- and high- grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions "caught in the act". Am J Clin Pathol. 2006; 126(4):564-571.

(19.) Chung SM, Chen YT, Panczykowski A, Schamber N, Klimstra DS, Yantiss RK. Serrated polyps with 'intermediate features' of sessile serrated polyp and microvesicular hyperplastic polyp: a practical approach to the classification of nondysplastic serrated polyps. Am J Surg Pathol. 2008; 32(3):407-412.

(20.) Bettington M, Walker N, Clouston A, et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology. 2013; 62: 367-386.

(21.) Carr NJ, Mahajan H, Tan KL, Hawkins NJ, Ward RL. Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol. 2009; 62(6):516-518.

(22.) Hetzel JT, Huang CS, Coukos JA, et al. Variation in the detection of serrated polyps in an average risk colorectal cancer screening cohort. Am J Gastroenterol. 2010; 105(12):2656-2664.

(23.) Pai RK, Hart J, Noffsinger AE. Sessile serrated adenoma strongly predispose to synchronous serrated polyps in non-syndrome patients. Histopathology. 2010; 56(5):581-588.

(24.) Spring KJ, Zhao ZZ, Karamatic R, et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology. 2006; 131(5):1400-1407.

(25.) Anderson JC, Rangasamy P, Rustagi T, et al. Risk factor for sessile serrated adenomas. J Clin Gastroenterol. 2011; 45(8):694-699.

(26.) Burnett-Hartman AN, Passarelli MN, Adams SV, et al. Differences in epidemiologic risk factors for colorectal adenomas and serrated polyps by lesion severity and anatomical site. Am J Epidemiol. 2013; 177(7):625-637.

(27.) Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010; 138(6):2088-2100.

(28.) Hunag CS, Farraye FA, Yang S, O'Brien MJ. The clinical significance of serrated polyps. Am J Gastroenterol. 2011; 106(2):229-240.

(29.) Boparai KS, Mathus-Vliegen EM, Koornstra JJ, et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. Gut. 2010; 59(8):1094-1100.

(30.) Guarinos C, Sanchez-Fortun C, Rodriguez-Soler M, et al. Serrated polyposis syndrome: molecular, pathological and clinical aspects. World J Gastroenterol. 2012; 18(20):2452-2461.

(31.) Jasperson KW, Kanth P, Kirchhoff AC, et al. Serrated polyposis: colonic phenotype, extracolonic features, and familial risk in a large cohort. Dis Colon Rectum. 2013; 56(11); 1211-1216.

Juliana F. Yang, MD; Shou-Jiang Tang, MD; Richard H. Lash, MD; Ruonan Wu, MSE; Qinghua Yang, MD, PhD

Accepted for publication April 21, 2014.

From the Department of Internal Medicine, Medical College of Wisconsin, Milwaukee (Dr Yang); the Division of Digestive Diseases, Department of Internal Medicine, The University of Mississippi Medical Center, Jackson (Dr Tang and Ms Wu); and Miraca Life Sciences Research Institute, Irving, Texas (Drs Lash and Yang).

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Qinghua Yang, MD, PhD, Miraca Life Sciences Research Institute, 6655 N MacArthur Blvd, Irving, TX 75039 (e-mail: qyang@

Caption: Figure 1. A, Sessile serrated adenoma/polyp (SSA/P) showing abnormal dilation with inverted T- or L-shaped crypts. B, SSA/P with low-grade cytologic dysplasia with abnormal dilation, nuclear pseudostratification, and hyperchromasia (upper portion of the specimen). C, SSA/P with highgrade cytologic dysplasia characterized by dysplastic glandular epithelium with increased cytologic pleomorphism and architectural complexity, including cribiforming (left of the specimen). D, SSA/P with adenocarcinoma with angulated dysplastic glands surrounded by desmoplasia (hematoxylin-eosin, original magnification x10).

Caption: Figure 2. Mapping of sessile serrated adenoma/polyp (SSA/P), SSA/P with low-grade cytologic dysplasia (SSA/P-LGD), and SSA/P with high-grade cytologic dysplasia (SSA/P-HGD). All occurred throughout the colon but are more concentrated in the proximal colon. Abbreviation: F, flexure.

Caption: Figure 3. Distribution of sessile serrated adenoma/polyp (SSA/P) and more advanced lesions in the colon. The graph highlights the concentration in the proximal colon (P < .001). Compared with the proximal colon, both transverse and distal colon show a similarly low prevalence of SSA/P with and without cytologic dysplasia. Abbreviations: SSA/P-HGD, SSA/P with high-grade cytologic dysplasia; SSA/P-LGD, SSA/P with low-grade cytologic dysplasia.

Caption: Figure 4. Endoscopic images of 2 sessile serrated adenomas/polyps (SSA/Ps) under white light (A and B) and narrow banding imaging (C and D): a mucus-covered polypoid SSA/P in the ascending colon (A and C) and another flat SSA/P in the cecum (B and D).
Table 1. Patients' Demographic Data

                                  SSA/P              SSA/P-LGD

No. (%) of patients         10 646 (95.0)        514 (4.6)
Men, No. (%)                4965 (46.6)          209 (40.7)
Women, No. (%)              5681 (53.4)          305 (59.3)
Male to female ratio        1/1.1                1/1.5
Age, mean [+ or -] SD (a)   60.8 [+ or -] 11.2   65.6 [+ or -] 11.1
Age range, y                19-92                39-92

                                SSA/P-HGD           SSA/P-ACA

No. (%) of patients         39 (0.4)            2 (0.018)
Men, No. (%)                11 (28.2)           0
Women, No. (%)              28 (71.8)           2
Male to female ratio        1/2.5               0/2
Age, mean [+ or -] SD (a)   69.9 [+ or -] 9.3   62.0 [+ or -] 11.3
Age range, y                51-85               54-70


No. (%) of patients         11 201 (100)
Men, No. (%)                5185 (46.3)
Women, No. (%)              6016 (53.7)
Male to female ratio        1/1.2
Age, mean [+ or -] SD (a)   61.0 [+ or -] 11.3
Age range, y                19-92

Abbreviations: SSA/P, sessile serrated adenoma/polyp; SSA/P-ACA,
SSA/P with adenocarcinoma; SSA/P-HGD, SSA/P with high-grade
cytologic dysplasia; SSA/P-LGD, SSA/P with low-grade cytologic

(a) The prevalence of dysplasia was significantly associated with a
patient's mean age: SSA/P versus SSA/P-LGD, P < .001; SSA/P versus
SSA/P-HGD, P < .001; and SSA/P-LGD versus SSA/P-HGD, P = .02.
Statistical analysis of SSA/P-ACA was not performed because of
limited numbers.

Table 2. Anatomic Location of Sessile Serrated Adenoma/Polyp (SSA/P)
and More Advanced Lesions in the Colon

Locations            SSA/P, No. (%)   SSA/P-LGD, No. (%)

Cecum                2509 (20.1)         95 (17.8)
Ascending            3895 (31.2)        169 (31.6)
Hepatic flexure      1045 (8.4)          50 (9.4)
Transverse           2333 (18.7)         94 (17.6)
Splenic flexure       243 (1.9)          10 (1.9)
Descending            882 (7.1)          42 (7.9)
Sigmoid              1107 (8.9)          43 (8.1)
Rectosigmoid           57 (0.46)          4 (0.7)
Rectum                157 (1.3)          12 (2.2)
Labeled "right"       135 (1.1)           9 (1.7)
Labeled "left"         22 (0.2)             0
NOS/random            111 (0.9)           6 (1.1)

Total                  12 496             534

Proximal colon (a)   7584 (61.2)        323 (61.2)
Transverse           2333 (18.8)         94 (17.8)
Distal colon (b)     2468 (19.9)        111 (21.0)

Total (c)              12 385             528

Locations            SSA/P-HGD, No. (%)   SSA/P-ACA, No. (%)

Cecum                   15 (37.5)             1 (50.0)
Ascending               13 (32.5)             1 (50.0)
Hepatic flexure          4 (10.0)               0
Transverse               4 (10.0)               0
Splenic flexure            0                    0
Descending               3 (7.5)                0
Sigmoid                  1 (2.5)                0
Rectosigmoid               0                    0
Rectum                     0                    0
Labeled "right"            0                    0
Labeled "left"             0                    0
NOS/random                 0                    0

Total                     40                    2

Proximal colon (a)      32 (80)               2 (100)
Transverse               4 (10.0)             0 (0)
Distal colon (b)         4 (10.0)             0 (0)

Total (c)                 40                    2

Locations            Total, No. (%)

Cecum                2620 (20)
Ascending            4078 (31.2)
Hepatic flexure      1099 (8.4)
Transverse           2431 (18.6)
Splenic flexure       253 (1.9)
Descending            927 (7.1)
Sigmoid              1151 (8.8)
Rectosigmoid           61 (0.5)
Rectum                169 (1.3)
Labeled "right"       144 (1.1)
Labeled "left"         22 (0.2)
NOS/random            117 (0.9)

Total                  13 072

Proximal colon (a)   7941 (61.3)
Transverse           2431 (18.8)
Distal colon (b)     2583 (20.0)

Total (c)              12 955

Abbreviations: NOS, not otherwise specified; SSA/P, sessile
serrated adenoma/polyp; SSA/P-ACA, SSA/P with adenocarcinoma;
SSA/P-HGD, SSA/P with high-grade cytologic dysplasia; SSA/P-LGD,
SSA/P with low-grade cytologic dysplasia.

(a) Proximal colon includes: cecum, ascending, hepatic flexure and
labeled "right" colon biopsies.

(b) Distal colon includes: splenic flexure, descending, sigmoid,
recto-sigmoid, rectum and labeled "left" colon biopsies.

(c) Numbers of SSA/P and more advanced lesions labeled as[down arrow]
NOS/Random were not included in the classification of proximal,
transverse, and distal colon.
COPYRIGHT 2015 College of American Pathologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Yang, Juliana F.; Tang, Shou-Jiang; Lash, Richard H.; Wu, Ruonan; Yang, Qinghua
Publication:Archives of Pathology & Laboratory Medicine
Date:Mar 1, 2015
Previous Article:High Collagen I Gene Expression as an Independent Predictor of Adverse Renal Outcomes in Lupus Nephritis Patients With Preserved Renal Function.
Next Article:Clear Cell Sarcoma-like Tumor of the Gastrointestinal Tract: An Evolving Entity.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |